Coagulation in Acute Aortic Dissection
Key facts
- Who runs it
- Ivy susanne Modrau, MD
- Where
- Denmark1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 26 people enrolled
- Started
- 1 Nov 2022
- Ended
- 15 Dec 2024
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Individualized HDR-approach
- Conventional ACT-approach
- Record updated
- 18 July 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Age > 18 years
- Emergent Acute Aortic Dissection with cardiopulmonary bypass
- Incapable of providing informed consent
Who cannot take part
- Previous open cardiac surgery
- History of congenital coagulation disorder (haemophilia)
- Death during induction of anaesthesia
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Acute aortic dissection (AAD) involving the ascending aorta (Stanford classification type A) remains a life-threatening disease. Excessive perioperative bleeding requiring massive transfusion of allogeneic blood products, and surgical reexploration remain major challenges in these patients. Previous research has indicated that patients with AAD show pronounced haemostatic alterations prior to surgery which are aggravated during major aortic surgery with cardiopulmonary bypass and hypothermia full heparinization.
Read full original descriptionShow less
Intensified anticoagulation management guided by heparin dose response (HDR) calculation, and repeated measurement of heparin concentration may be more effective than standard empiric weight-based heparin and protamine management monitored by activated clotting time (ACT) measurements to suppress thrombin generation during surgery for AAD.
This randomized controlled clinical trial compares the impact of two recommended anticoagulation management strategies during surgery for AAD including deep hypothermia on activation of coagulation: Heparin/protamine-management based on HDR-titration by means of HMS Plus® versus current institutional standard (HDR- versus ACT-approach).
Primary endpoint is thrombin generation as measured by early postoperative prothrombin fragment 1+2 (F1+2). Secondary endpoints are other markers of coagulation and fibrinolysis as well as clinical outcome.
The 2 groups in the trial
- Individualised HDR-approachExisting treatment, for comparison
HMS Plus® Hemostasis Management System (Medtronic International, Tolochenaz, CH).
Treatment: Individualized HDR-approach
- Conventional ACT-approachExisting treatment, for comparison
ACT Hemostasis Management
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Impact of Anticoagulation Management on Thrombin Generation During Surgery for Acute Aortic Dissection
- Publications
- Heparin management and coagulation in acute aortic dissection surgery: a randomized controlled trial.Journal of thrombosis and haemostasis : JTH, 2026
- Record updated
- 18 July 2025